Dr. John Cush RheumNow
1 year ago
Manifestations and Treatment in Relapsing Polychondritis
A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease.
https://t.co/Gz2qwtC4jZ https://t.co/ZLkjNQmbRC
Dr. John Cush RheumNow
1 year ago
Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients
More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the https://t.co/gjJOjZhSHU
Dr. John Cush RheumNow
1 year ago
Stroke in patients with SLE is associated with a poorer outcome than matched controls in
terms of functional recovery, recurrence, and mortality - study of 40 SLE vs 120 controls w/ CVA https://t.co/spBT1u6bfj https://t.co/eVNYBogJWz
Dr. John Cush RheumNow
1 year ago
Full read overview of new imaging modalities for inflammatory arthritis, including high-res.quantitative CT, ultra-high field MRI), PET, fluorescence optical imaging, optoacoustic imaging, contrast-enhanced ultrasonography - all with artificial intelligence analysis https://t.co/3w5RZEUC9K
New survey data from the Orlando Health Spine Center reveals a significant difference among Americans on how to manage neck and back pain. Respondents were split between relying on rest and reduced activity (44%), turning to over-the-counter pain relievers (42%), and hot/cold therapies (29%) — an uncertainty that may be discouraging some from seeking medical guidance.
Dr. John Cush RheumNow
1 year ago
SSB, > SSA, Abs are signif associated w/ abnormal DLCO (AUC 0.791) in Sjogrens syndrome, esp in assoc. w/ LIP- lymphocytic interstitial pneumonitis. These findings more likely in quadruple positive Sjogrens w/ RF/ANA/SSA/SSB positivity. https://t.co/s6IyRzfXiN https://t.co/J3bMowsrUQ
Dr. John Cush RheumNow
1 year ago
Metanalysis of Uveitis & JIA - 28 studies, 22,834 JIA pts w/ 3,381dx w/ uveitis - prevalence = 12.7%,, highest in Europeans (14.3%), lowest in Asian (6.5%). Uveitis risk factors included early age JIA onset, ANA-positive, and increased ESR. https://t.co/MxffJKvbik https://t.co/LDz60uwQTM
Machine learning analysis of pre-treatment synovial tissue biopsy from rheumatoid arthritis (RA) patients starting either etanercept (ETN), tocilizumab (TCZ) and rituximab (RTX) revealed high accuracy prediction of 16 week outcomes unique to each biologic.
Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA. Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).This most recent analysis of the prevalence and distribution of arthritis subtypes in the US, used data from NHANES 2020 (National Health and Nutrition Examination Survey) that collected data from 2017 to March 2020 .
Dr. John Cush RheumNow
1 year ago
Sulfasalazine as a preventative against Pneumocystis (PJP). 594 RA pts & 848 Rx episodes - 181 on SSZ, 667 controls. W/ 850 Pt-Yrs F/U, 21developed PCP, 3 died of PCP. SSZ significantly lowered PJP risk (p = 0.003, rate ratio = 0.05; 95% CI 0.00–0.34). https://t.co/PAgBaJGldR https://t.co/VV3MvVEGal
Dr. John Cush RheumNow
1 year ago
Osteoporosis treatment benefits people older than 80
People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San https://t.co/ry3V4Nmq7E
Dr. John Cush RheumNow
1 year ago
New download available on biomarkers
https://t.co/rFeApBnHav https://t.co/vwjog6ILJU
Dr. John Cush RheumNow
1 year ago
Interstitial Lung Disease and Lung Cancer Risk
A large prospective cohort study found that interstitial lung disease (ILD) is associated with an increased risk of lung cancer.
https://t.co/SdOT28qVfr https://t.co/6KhAijhfHw
Dr. John Cush RheumNow
1 year ago
Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/IDeEvitIrB
Dr. John Cush RheumNow
1 year ago
Biologic survival study of British Assoc. of Dermatologists Biologics Register (11/07-6/23) looked at 19,034 Rx courses (median F/U 2.3 yrs), of TNFi, IL-12/23i, IL-17i, & IL-23i. IL-23i (GUS & RIS) had best survival (~1.93yrs) for efficacy & safety (broadalumab the least) https://t.co/aAULb0e3o9
